Wall Street brokerages expect that Gamida Cell Ltd. (NASDAQ:GMDA) will announce earnings of ($0.38) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Gamida Cell’s earnings, with the highest EPS estimate coming in at ($0.35) and the lowest estimate coming in at ($0.42). Gamida Cell reported earnings per share of ($0.37) during the same quarter last year, which indicates a negative year-over-year growth rate of 2.7%. The company is scheduled to issue its next quarterly earnings report on Tuesday, August 10th.
According to Zacks, analysts expect that Gamida Cell will report full-year earnings of ($1.58) per share for the current fiscal year, with EPS estimates ranging from ($1.83) to ($1.43). For the next financial year, analysts expect that the business will report earnings of ($1.39) per share, with EPS estimates ranging from ($1.97) to ($0.58). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Gamida Cell.
Gamida Cell (NASDAQ:GMDA) last posted its quarterly earnings results on Monday, May 10th. The company reported ($0.31) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.40) by $0.09.
Shares of GMDA stock opened at $6.58 on Friday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 8.97 and a current ratio of 8.97. The company has a 50 day moving average of $7.03. Gamida Cell has a 52 week low of $3.86 and a 52 week high of $15.00. The firm has a market capitalization of $159.37 million, a P/E ratio of -3.89 and a beta of 1.93.
A number of large investors have recently made changes to their positions in the stock. Federated Hermes Inc. raised its holdings in Gamida Cell by 184.2% during the fourth quarter. Federated Hermes Inc. now owns 5,052,523 shares of the company’s stock worth $42,391,000 after purchasing an additional 3,274,746 shares in the last quarter. Rock Springs Capital Management LP grew its position in Gamida Cell by 0.3% in the first quarter. Rock Springs Capital Management LP now owns 2,100,300 shares of the company’s stock worth $16,991,000 after buying an additional 6,300 shares during the last quarter. Baker BROS. Advisors LP grew its position in Gamida Cell by 144.5% in the fourth quarter. Baker BROS. Advisors LP now owns 1,548,314 shares of the company’s stock worth $12,990,000 after buying an additional 914,990 shares during the last quarter. JPMorgan Chase & Co. grew its position in Gamida Cell by 4,367,658.3% in the first quarter. JPMorgan Chase & Co. now owns 1,048,262 shares of the company’s stock worth $8,480,000 after buying an additional 1,048,238 shares during the last quarter. Finally, ARK Investment Management LLC grew its position in Gamida Cell by 108.2% in the first quarter. ARK Investment Management LLC now owns 670,324 shares of the company’s stock worth $5,423,000 after buying an additional 348,298 shares during the last quarter.
Gamida Cell Company Profile
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia.
Read More: Current Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.